COVID-19 has altered life sciences. Hear from Boehringer Ingelheim on how they digitized their legal and manufacturing processes in response to COVID-19. See newly released and upcoming product enhancements that improves the ability to attain internal and external signatures that are compliant with the FDA’s 21 CFR Part 11 regulations.